Informatie:
Fout:
ID
14522
Beschrijving
Vitamin D for the Treatment of Severe Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT00712205
Link
https://clinicaltrials.gov/show/NCT00712205
Trefwoorden
Versies (1)
- 19-04-16 19-04-16 -
Houder van rechten
CC BY-NC 3.0
Geüploaded op
19 april 2016
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Asthma NCT00712205
Eligibility Asthma NCT00712205
- StudyEvent: Eligibility
Similar models
Eligibility Asthma NCT00712205
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
outpatients
Item
20 outpatients of either sex,
boolean
C0029921 (UMLS CUI [1])
age and persistent asthma
Item
ages ≥18 years, with a history of persistent asthma as defined by the american thoracic society (ats) will be eligible for entry into the study.
boolean
C0001779 (UMLS CUI [1])
C3266628 (UMLS CUI [2])
C3266628 (UMLS CUI [2])
ics treatment
Item
additionally, patients must have been previously treated with ics for at least 4 weeks at a stable dose equivalent to ≥400 ug/day beclomethasone dipropionate.
boolean
C3248292 (UMLS CUI [1,1])
C0040223 (UMLS CUI [1,2])
C0004906 (UMLS CUI [2])
C0040223 (UMLS CUI [1,2])
C0004906 (UMLS CUI [2])
pre-bronchodilator fev1
Item
patients will be required to have a forced expiratory volume in 1 s (fev1) between 40-85% of predicted normal before the use of an inhaled bronchodilator and to demonstrate at least one of the following:
boolean
C3172227 (UMLS CUI [1])
post-bronchodilator fev1
Item
an improvement in fev1 ≥ 12% and ≥ 200 ml within 15-30 min after inhalation of salbutamol 200-400 ug;
boolean
C0748133 (UMLS CUI [1,1])
C2599594 (UMLS CUI [1,2])
C0001927 (UMLS CUI [1,3])
C2599594 (UMLS CUI [1,2])
C0001927 (UMLS CUI [1,3])
methacholine challenge
Item
airway hyperresponsiveness to methacholine causing a 20% decline in fev1 (pc20 fev1) at a concentration of < 16 mg/ml;
boolean
C0430567 (UMLS CUI [1,1])
C0748133 (UMLS CUI [1,2])
C0748133 (UMLS CUI [1,2])
pef variability
Item
diurnal peak expiratory flow (pef) variability of ≥ 15% during at least 3 of 7 days before randomization.
boolean
C0030735 (UMLS CUI [1,1])
C2827666 (UMLS CUI [1,2])
C2827666 (UMLS CUI [1,2])
asthma exacerbation or respiratory tract infection or hospitalization for asthma
Item
patients with either an exacerbation of asthma or respiratory tract infection within 6 weeks or admission to a hospital for asthma within 6 weeks before the study will be excluded.
boolean
C0349790 (UMLS CUI [1])
C0009450 (UMLS CUI [2,1])
C0458827 (UMLS CUI [2,2])
C0019993 (UMLS CUI [3,1])
C0004096 (UMLS CUI [3,2])
C0040223 (UMLS CUI [4])
C0009450 (UMLS CUI [2,1])
C0458827 (UMLS CUI [2,2])
C0019993 (UMLS CUI [3,1])
C0004096 (UMLS CUI [3,2])
C0040223 (UMLS CUI [4])
nighttime symptoms and beta-2 agonists
Item
also patients will not be eligible if they had > 3 nights with awakenings due to asthma that required treatment with short-acting betamimetics or had 3 days when they required > or = 12 puffs/d short-acting betamimetics during the 7days before the randomization visits.
boolean
C1273489 (UMLS CUI [1,1])
C0860510 (UMLS CUI [1,2])
C1373132 (UMLS CUI [2])
C0860510 (UMLS CUI [1,2])
C1373132 (UMLS CUI [2])
potency greater than inhaled steroid
Item
patients will also excluded if they use medications greater potency than inhaled steroid, e.g.not leukotriene inhibitors or anti-ige (xolair®).
boolean
C2065041 (UMLS CUI [1,1])
C0678792 (UMLS CUI [1,2])
C0678792 (UMLS CUI [1,2])
copd and smoking history
Item
patients with chronic obstructive pulmonary disease and current or former smokers of >10 pack-years
boolean
C0024117 (UMLS CUI [1])
C1519384 (UMLS CUI [2])
C1277691 (UMLS CUI [3])
C1519384 (UMLS CUI [2])
C1277691 (UMLS CUI [3])